User menu

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

Bibliographic reference Neyns, Bart ; Chaskis, Cristo ; Joosens, Eric ; Menten, Johan ; D'Hondt, Lionel ; et. al. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.. In: Cancer Investigation, Vol. 26, no.3, p. 269-77 (2008)
Permanent URL
  1. Louis David N., Ohgaki Hiroko, Wiestler Otmar D., Cavenee Webster K., Burger Peter C., Jouvet Anne, Scheithauer Bernd W., Kleihues Paul, The 2007 WHO Classification of Tumours of the Central Nervous System, 10.1007/s00401-007-0243-4
  2. J. Clin. Oncol., 19, 509 (2001)
  3. Levin Victor A., Silver Pamela, Hannigan John, Wara William M., Gutin Philip H., Davis Richard L., Wilson Charles B., Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarrazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report, 10.1016/0360-3016(90)90096-3
  4. Yung W. K., Temodal Brain Tumor Group. J. Clin. Oncol., 17, 2762 (1999)
  5. Brada M., Hoang-Xuan K., Rampling R., Dietrich P-Y., Dirix L. Y., Macdonald D., Heimans J. J., Zonnenberg B. A., Bravo-Marques J. M., Henriksson R., Stupp R., Yue N., Bruner J., Dugan M., Rao S., Zaknoen S., Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse, 10.1023/a:1008382516636
  6. Chang Susan M., Theodosopoulos Philip, Lamborn Kathleen, Malec Mary, Rabbitt Jane, Page Margaretta, Prados Michael D., Temozolomide in the treatment of recurrent malignant glioma, 10.1002/cncr.11949
  7. Everaert Els, Neyns Bart, Joosens Eric, Strauven Theo, Branle Fabrice, Menten Johan, Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium, 10.1023/b:neon.0000040809.97943.c0
  8. Yung W. K., procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer., 83, 588 (2000)
  9. Tolcher A W, Gerson S L, Denis L, Geyer C, Hammond L A, Patnaik A, Goetz A D, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler D L, Rowinsky E K, Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules, 10.1038/sj.bjc.6600827
  10. Michotte A., Acta. Neurol. Belg., 104, 148 (2004)
  11. Macdonald D. R., J. Clin. Oncol., 8, 1277 (1990)
  12. Esteller Manel, Garcia-Foncillas Jesus, Andion Esther, Goodman Steven N., Hidalgo Oscar F., Vanaclocha Vicente, Baylin Stephen B., Herman James G., Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating Agents, 10.1056/nejm200011093431901
  13. Hegi Monika E., Diserens Annie-Claire, Gorlia Thierry, Hamou Marie-France, de Tribolet Nicolas, Weller Michael, Kros Johan M., Hainfellner Johannes A., Mason Warren, Mariani Luigi, Bromberg Jacoline E.C., Hau Peter, Mirimanoff René O., Cairncross J. Gregory, Janzer Robert C., Stupp Roger, MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma, 10.1056/nejmoa043331
  14. Paz M. F., CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas, 10.1158/1078-0432.ccr-04-0392
  15. Tosoni A., Cavallo G., Ermani M., Scopece L., Franceschi E., Ghimenton C., Gardiman M., Pasetto L., Blatt V., Brandes A. A., Is protracted low-dose temozolomide feasible in glioma patients?, 10.1212/
  16. Brandes A A, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crinò L, Ermani M, Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO), 10.1038/sj.bjc.6603376
  17. Wick Antje, Felsberg Jörg, Steinbach Joachim P., Herrlinger Ulrich, Platten Michael, Blaschke Britta, Meyermann Richard, Reifenberger Guido, Weller Michael, Wick Wolfgang, Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma, 10.1200/jco.2007.10.7722
  18. Wick W., Steinbach J. P., Kuker W. M., Dichgans J., Bamberg M., Weller M., One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma, 10.1212/01.wnl.0000127617.89363.84
  19. Wick Wolfgang, Weller Michael, How Lymphotoxic Is Dose-Intensified Temozolomide? The Glioblastoma Experience, 10.1200/jco.2004.00.8417
  20. Su Y.B., Sohn Sejean, Krown Susan E., Livingston Philip O., Wolchok Jedd D., Quinn Carolyn, Williams Linda, Foster Theresa, Sepkowitz Kent A., Chapman Paul B., Selective CD4+Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications, 10.1200/jco.2004.07.060
  21. Stupp R., Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide, 10.1200/jco.20.5.1375
  22. van den Bent M. J., J. Clin. Oncol., 23, 114s (2005)
  23. Cairncross G., J. Clin. Oncol., 23, 107 (2004)
  24. Chahlavi Ali, Kanner Andrew, Peereboom David, Staugaitis Susan M., Elson Paul, Barnett Gene, 10.1023/a:1022580610598
  25. Carlini Paolo, Papaldo Paola, Fabi Alessandra, Felici Alessandra, Ruggeri Enzo Maria, Milella Michele, Ciccarese Mariangela, Nuzzo Carmen, Cognetti Francesco, Ferretti Gianluigi, Liver Toxicity After Treatment With Gefitinib and Anastrozole: Drug-Drug Interactions Through Cytochrome p450?, 10.1200/jco.2006.07.8261
  26. Repetto Lazzaro, Audisio Riccardo A., Elderly Patients Have Become the Leading Drug Consumers: It's High Time to Properly Evaluate New Drugs Within the Real Targeted Population, 10.1200/jco.2006.09.3039
  27. Rizek P., Can. J. Neurol. Sci., 31, S9 (2004)
  28. US National Institutes of Health, Radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma or gliosarcoma
  29. European Organisation for Research and Treatment of Cancer: Brain tumour group: ongoing trials. Available at Accessed September 24, 2007